

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yunkang Group Limited

云康集团有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2325)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Yunkang Group Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) on a voluntary basis to provide shareholders and potential investors of the Company with the latest business update of the Group.

FORMATION OF JOINT VENTURE

The board of directors of the Company (the “**Board**”) hereby announces that on July 1, 2022, a joint venture agreement (the “**JV Agreement**”) was entered into among our Group, GIRM Biosafety (Guangzhou) Co., Ltd. (呼研所生物安全科技(廣州)股份有限公司) (“**GIRM**”), a subsidiary of Innovita Biological Technology Co., Ltd. (北京英諾特生物技術股份有限公司) (“**Innovita**”), and a subsidiary of Guangzhou Daan Incubator Enterprise Management Co., Ltd. (廣州達安創谷企業管理有限公司) (“**Daan Incubator**”) for the purpose of establishing a joint venture company (the “**JV Company**”).

To the best of the Directors’ knowledge, information and belief, having made all reasonable enquiries, Innovita, GIRM and Daan Incubator are third parties independent of the Company and connected persons of the Company as at the date of this announcement.

REASONS FOR AND BENEFITS

The JV Company will establish a primary-level rapid detection network for respiratory diseases based on medical institution alliances and healthcare service institutions. Leveraging the respective resources and advantages in the healthcare industry of parties, the formation of JV Company will achieve rapid screening and classification of high-risk people and establish primary-level early detection and prevention systems, thereby providing support for the gradual and orderly easing of COVID-19 pandemic prevention and control.

As a diagnostic service provider for medical institution alliance in China, the Company boasts the professional medical diagnostic service capabilities, strong standardization capabilities, and an innovative diagnostic testing service model. The Company will fully leverage nationwide operation service network of medical institution alliance and internationally-advanced standardized quality control system to bring the newest and most cutting-edge disease prevention and diagnosis technologies to the primary level cities. The Company believes that the cooperation under the JV Agreement will facilitate the expansion of the service network down to the primary level, enhance the market presence, and have a positive impact on the on-going operation of the Group.

INFORMATION OF THE PARTIES

GIRM

GIRM is an industry-university-research base of the State Key Laboratory of Respiratory Diseases (“SKLRD”), and a high-tech enterprise in the National University Science Park engaged in biosafety projects focusing on pandemic prevention technologies. Backed by Guangzhou Medical University and established with the approval the Ministry of Science and Technology in October 2007, SKLRD is the only national key laboratory in the field of respiratory disease research in China. The first director of SKLRD was Academician Zhong Nanshan (鐘南山院士).

Innovita

Innovita is a biotechnology company specialized in research and development, manufacturing and sales of Point of Care Testing in vitro diagnostic products. Innovita specializes in the detection of respiratory pathogens and the combined detection of multiple pathogens.

Daan Incubator

Focusing on building a boundaryless incubator for the grand health industry, Daan Incubator integrates the internal and external resources of the Daan Incubator ecosystem through a unique “enterprise mutual incubation” model to facilitate resource circulation among incubated enterprises and help enterprises achieve rapid development.

GENERAL

As none of the applicable percentage ratios (as defined in Rule 14.07 of the Rules Governing the Listing of Securities on the Stock Exchange (“**Listing Rules**”)) for the formation of the JV Company exceed 5%, the transaction under the JV Agreement does not constitute a notifiable transaction of the Company under Chapter 14 of Listing Rules.

By order of the Board
Yunkang Group Limited
Zhang Yong
Chairman

Guangzhou, the PRC
July 1, 2022

As at the date of this announcement, the executive director, Chairman and Chief Executive Officer of the Company is Mr. Zhang Yong; the non-executive directors of the Company are Mr. Zhou Xinyu, Dr. Guo Yunzhao and Mr. Zhou Weiqun; and the independent non-executive directors of the Company are Mr. Yu Shiyou, Mr. Yang Hongwei and Mr. Xie Shaohua.